LisamarieLoGiudice Ph.D.

Associate

New York + 1.212.326.8387

Dr. Lisamarie LoGiudice's intellectual property practice is focused on pharmaceutical and biotechnology patent litigation in district court and post-grant invalidity proceedings before the USPTO's Patent Trial and Appeal Board. Her litigation experience spans pre-lawsuit investigation all the way through appeals to the Federal Circuit. She also has experience providing patent prosecution strategy advice, due diligence evaluations of patent portfolios, analyzing the validity of patents, and freedom-to-operate analyses.

Prior to joining Jones Day, Lisamarie received a doctorate in neuroscience from Stony Brook University where her research focused on the mechanisms and molecular underpinnings of synaptic transmission. During her time at Stony Brook, she coauthored several peer-reviewed publications in the fields of molecular and cellular neurobiology.

Experience

  • R.J. Reynolds and Philip Morris engage in patent battle related to tobacco heating products and vaping productsJones Day is representing R.J. Reynolds Tobacco Company ("Reynolds") and R.J. Reynolds Vapor Company ("RJRV") in several U.S. actions as part of its global patent dispute related to tobacco heating and vaping products. Reynolds filed patent infringement complaints against Philip Morris and Altria entities in the U.S. International Trade Commission and in the U.S. District Court in the Eastern District of Virginia, alleging that Philip Morris' IQOS tobacco heating product infringes a number of Reynolds' patents.
  • Takeda prevails in Hatch-Waxman Act trial relating to diabetes productsJones Day successfully represented Takeda Pharmaceutical Company Ltd. in a Hatch-Waxman Act trial against companies seeking to market generic versions of three diabetes products prior to the expiration of Takeda's patents.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against IntellipharmaceuticsJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of a Section 505(b)(2) New Drug Application to the FDA seeking approval of an extended-release oxycodone formulation.
  • Purdue Pharma successfully moves for additional discovery regarding real-party-in-interest, leading to termination of IPRs before institutionJones Day defended patent owner, Purdue Pharma L.P., in connection with two inter partes review (IPR) petitions brought by the petitioner, Kashiv Pharma, LLC, against U.S. Patent Nos. 9,492,392 and 9,492,393.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Epic Pharma related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Epic Pharma, LLC and PuraCap Pharmaceutical LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of OxyContin®.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Amneal and Kashiv related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Amneal Pharmaceuticals, LLC and Kashiv Pharma, LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Celgene prevails in Apotex and Cipla IPR challenges of Abraxane® patentsJones Day served as lead counsel and successfully defended Celgene Corporation in connection with six inter partes review (IPR) petitions filed by Apotex or Cipla against U.S. Patent Nos. 8,138,229, 7,820,788, and 7,923,536, which are related to formulations for Celgene's chemotherapeutic drug marketed as Abraxane®.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against AbhaiJones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against the defendant, Abhai LLC's, submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed drug for pain relief.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against MylanJones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against KVK-Tech and AbhaiJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Celgene successfully defends REVLIMID® compound patent against Kyle Bass' IPR petitionJones Day represented Celgene Corporation in successfully defending an IPR petition filed by Coalition for Affordable Drugs VI LLC (CFAD) - a company formed by hedge fund manager Kyle Bass - against U.S. Patent No. 5,635,517, which is listed in the Orange Book for Celgene's REVLIMID® brand drug.
  • AbbVie subsidiary asserts patent infringement claims under Hatch-Waxman Act related to AndroGel® against Perrigo and WatsonJones Day represented Unimed Pharmaceuticals, LLC, a subsidiary of AbbVie, Inc., in a consolidated Hatch-Waxman patent infringement action against Perrigo Company and Watson Laboratories, Inc., relating to the defendants' submission of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of AndroGel® 1.62%, a widely-prescribed treatment for males with low testosterone levels.
  • Celgene defends REMS patents against Kyle Bass' IPR petitionsJones Day is representing Celgene Corporation in defending four IPR petitions filed by Coalition for Affordable Drugs VI LLC - a company formed by hedge fund manager Kyle Bass - against U.S. Patent Nos. 6,045,501 and 6,315,720, which are listed in the Orange Book for Celgene's REVLIMID®, POMALYST®, and THALOMID® brand drugs, and which pertain to Celgene's Risk Evaluation and Mitigation Strategy (REMS)™ for those drugs.
  • Purdue Pharma pursues patent infringement suit involving OxyContin(R) against generic drug maker TevaJones Day represents Purdue Pharma L.P., The P.F. Laboratories, Inc., and Purdue Pharmaceuticals L.P. in a Hatch-Waxman Act patent infringement litigation matter relating to Teva Pharmaceuticals USA, Inc.'s attempt to market a generic version of Purdue's controlled-release OxyContin(R) pain relief medication.
  • Linedata acquires HCL Technologies' CapitalStream businessJones Day advised Linedata Services, S.A. in its acquisition of HCL Technologies' CapitalStream business and entry into a strategic partnership with HCL Technologies Ltd.
  • Purdue Pharma defends against claims of patent infringementJones Day represents Purdue Pharma L.P., The P.F. Laboratories, Inc., and Purdue Pharmaceuticals L.P. in a patent infringement litigation brought by plaintiff Depomed, Inc., based on Purdue's manufacture and sale of its own patented controlled-release OxyContin(R) pain relief medication.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.